Caroline Palomeque
Stock Analyst at Maxim Group
(1.30)
# 3,616
Out of 4,996 analysts
10
Total ratings
44.44%
Success rate
-0.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Upgrades: Buy | $8 | $2.09 | +282.78% | 3 | Sep 4, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $27.51 | +114.47% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $167.82 | -8.24% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $73.75 | -21.36% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $191.99 | -13.54% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $13.95 | +179.57% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $9.65 | +532.12% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $8.66 | +361.89% | 1 | Jun 23, 2022 |
Daré Bioscience
Sep 4, 2025
Upgrades: Buy
Price Target: $8
Current: $2.09
Upside: +282.78%
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $27.51
Upside: +114.47%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $167.82
Upside: -8.24%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $73.75
Upside: -21.36%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $191.99
Upside: -13.54%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $13.95
Upside: +179.57%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $9.65
Upside: +532.12%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $8.66
Upside: +361.89%